Repurposing AKT Inhibitors for the Treatment of Protein Misfolding and Protein Trafficking Diseases
<- Return to Search Page
- Categories
- Biotechnology, Pharmaceuticals
- Summary
- WSU investigators have demonstrated that inhibition of pro-survival kinase, AKT, using the transgene, Trb3, expressed in oligodendrocytes, leads to less brain white matter than controls. Moreover, Trb3 introduction into an animal model of the human disease, Pelizaeus Merzbacher disease (PMD) leads to less myelin thickness and fewer disease symptoms than untreated animals. These results suggest inhibiting AKT msy ameliorate the symptons of PDM and other diseases with similar or analogous pathophysiology such as Alzheimer and Parkinson’s disease to name a few.
- File number
- 08-899
- Publications
- We are seeking industrial partners to further develop this technology by characterizing biologic or small molecule inhibitors of AKT. A patent application is on file.
- Contact
- Randy Ramharack
Technology Licensing Manager
Phone: 313-577-5541
Fax : 313-577-2814
randy.ramharack@wayne.edu